Recruiting
Phase 3

JNT-517

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Code:

NCT06971731

Conditions

Phenylketonuria

Eligibility Criteria

Sex: All

Age: 4+

Healthy Volunteers: Not accepted

Interventions

JNT-517

JNT-517 Matching Placebo

Study Details

Brief summary:

This Phase 3 study will evaluate the safety, effectiveness, tolerability, and how the body processes JNT-517 in children, adolescents, and adults with phenylketonuria.

Participants will be randomly assigned to receive either JNT-517 or placebo during an initial 6-week treatment period. After this period, eligible participants will receive JNT-517 for an additional 46 weeks.

Conditions

Phenylketonuria

Study ID

NCT06971731

Start date

Oct 20, 2025

Status verified date

Oct, 2026

Completion date

Apr 1, 2028

Anticipated

Primary completion date

Mar 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 4+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male or female participants aged 4 years or older.
2. Diagnosed with phenylketonuria.
3. Have phenylalanine levels that meet study requirements.
4. Meet study-specific requirements regarding current treatment for phenylketonuria.
5. Willing and able to follow study dietary requirements.
6. Weigh at least 12.5 kilograms.
7. If able to become pregnant or father a child, willing to follow the study's contraception requirements.
8. Any ongoing mental health condition must be stable before entering the study.
9. Able to provide informed consent (or have consent provided by a parent or legal guardian, when applicable) and comply with study procedures.

Exclusion Criteria:

Participants will be excluded from the study if any of the following criteria are met:

1. Significant medical condition that, in the investigator's opinion, could make participation unsafe or interfere with study participation.
2. Significant liver disease or impaired kidney function.
3. Certain eye conditions, including significant cataracts.
4. Active infection requiring medical evaluation.
5. History of certain cancers within the past 5 years.
6. Allergy or hypersensitivity to JNT-517 or its ingredients.
7. Prior treatment with JNT-517.
8. Recent participation in another investigational study or receipt of an investigational treatment that does not meet study requirements.
9. Use of medications that are not permitted during the study.
10. Abnormal laboratory or heart test results that would make study participation inappropriate.
11. Conditions that could affect the absorption of oral study medication.
12. History of recent substance or alcohol abuse.
13. Unwillingness to follow study requirements, including restrictions on intentional weight loss.

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: JNT-517 - High Dose

Participants will receive JNT-517 orally, twice daily (BID), with dosing determined by age, for 6 weeks in Period 1, followed by JNT-517 orally, BID for 46 weeks in Period 2.

experimental: JNT-517 - Low Dose

Participants will receive JNT-517 orally, BID, with dosing determined by age, for 6 weeks in Period 1, followed by JNT-517 orally for 46 weeks in Period 2.

placebo comparator: Placebo

Participants will receive JNT-517 matching placebo orally, BID for 6 weeks in Period 1, followed by JNT-517 orally, BID for 46 weeks in Period 2.

Interventions

JNT-517

JNT-517 orally

JNT-517 Matching Placebo

JNT-517 matching placebo orally

Primary outcome measure

  • Absolute Change in Plasma Phenylalanine (Phe) From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 High Dose BID Dose Group at End of Period 1 [ Time Frame: Baseline to End of Period 1 (Week 6) ]

Central Contacts and Locations

Locations

University of California Los Angeles (UCLA) School of Medicine

Recruiting

Los Angeles, California, United States, 90024

Contacts

Principal Investigator:

Nicola Longo

University of Florida (UF) Health Shands Hospital

Recruiting

Gainesville, Florida, United States, 32608

Contacts

Principal Investigator:

Roberto Zori

University of South Florida

Recruiting

Tampa, Florida, United States, 33606

Contacts

Principal Investigator:

Amarilis Sanchez-Valle

Ann & Robert H. Lurie Children's Hospital of Chicago

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Principal Investigator:

Erika Vucko

Oregon Health and Science University

Recruiting

Portland, Oregon, United States, 97239

Contacts

Principal Investigator:

Cary Harding

University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh

Recruiting

Pittsburgh, Pennsylvania, United States, 15201

Contacts

Principal Investigator:

Gerard Vockley

Vanderbilt University Medical Center

Recruiting

Nashville, Tennessee, United States, 37232

Contacts

Principal Investigator:

Scott Ward

University of Texas Southwestern

Recruiting

Dallas, Texas, United States, 75390

Contacts

Principal Investigator:

Markey McNutt

University of Texas Health (UTHealth) Science Center at Houston

Recruiting

Houston, Texas, United States, 77030-1501

Contacts

Principal Investigator:

Hope Northrup

Utah Health - The University of Utah Hospital

Recruiting

Salt Lake City, Utah, United States, 84112

Contacts

Principal Investigator:

Ashley Andrews

M.A.G.I.C Clinic

Recruiting

Calgary, Alberta, Canada, T2E 7H7

Contacts

Principal Investigator:

Aneal Khan

More Information

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Last update posted

Oct 21, 2026

Last verified

Oct, 2026

Keywords

  • Phenylketonuria
  • PKU

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-23. This information was provided to ClinicalTrials.gov by Otsuka Pharmaceutical Development & Commercialization, Inc. on 2026-10-21. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.